| Species |
Human |
| Protein Construction |
| monomeric hFc |
GITR Ligand/TNFSF18 Trimer (Gln50-Ser177)
Accession # Q9UNG2 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized GITR Ligand/TNFSF18 Trimer hFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Human GITR, His Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
70.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 75-85 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Glucocorticoid-induced TNFR-related protein (TNFRSF18, GITR, CD357), expressed by T cells, and its ligand (TNFSF18, GITRL), expressed by myeloid populations, provide co-stimulatory signals that boost T cell activity. Due to the important role that GITR plays in regulating immune functions, agonistic stimulation of GITR is a promising therapeutic concept. |
| Synonyms |
TNFSF18; AITRL; TL6; GITRL; GITR Ligand |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
